Soluble ST2 Levels and Left Ventricular Structure and Function in Patients With Metabolic Syndrome
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: A biomarker that is of great interest in relation to adverse cardiovascular events is soluble ST2 (sST2), a member of the interleukin family. Considering that metabolic syndrome (MetS) is accompanied by a proinflammatory state, we aimed to assess the relationship between sST2 and left ventricular (LV) structure and function in patients with MetS. Methods: A multicentric, cross-sectional study was conducted on180 MetS subjects with normal LV ejection fraction as determined by echocardiography. LV hypertrophy (LVH) was defined as an LV mass index greater than the gender-specific upper limit of normal as determined by echocardiography. LV diastolic dysfunction (DD) was assessed by pulse-wave and tissue Doppler imaging. sST2 was measured by using a quantitative monoclonal ELISA assay. Results: LV mass index (β=0.337, P<0 .001, linear regression) was independently associated with sST2 concentrations. Increased sST2 was associated with an increased likelihood of LVH [Exp (B)=2.20, P=0.048, logistic regression] and increased systolic blood pressure [Exp (B)=1.02, P=0.05, logistic regression]. Comparing mean sST2 concentrations (adjusted for age, body mass index, gender) between different LV remodeling patterns, we found the greatest sST2 level in the group with concentric hypertrophy. There were no differences in sST2 concentration between groups with and without LV DD. Conclusions: Increased sST2 concentration in patients with MetS was associated with a greater likelihood of exhibiting LVH. Our results suggest that inflammation could be one of the principal triggering mechanisms for LV remodeling in MetS.
Abstract
Background: A biomarker that is of great interest in relation to adverse cardiovascular events is soluble ST2 (sST2), a member of the interleukin family. Considering that metabolic syndrome (MetS) is accompanied by a proinflammatory state, we aimed to assess the relationship between sST2 and left ventricular (LV) structure and function in patients with MetS. Methods: A multicentric, cross-sectional study was conducted on180 MetS subjects with normal LV ejection fraction as determined by echocardiography. LV hypertrophy (LVH) was defined as an LV mass index greater than the gender-specific upper limit of normal as determined by echocardiography. LV diastolic dysfunction (DD) was assessed by pulse-wave and tissue Doppler imaging. sST2 was measured by using a quantitative monoclonal ELISA assay. Results: LV mass index (β=0.337, P<0 .001, linear regression) was independently associated with sST2 concentrations. Increased sST2 was associated with an increased likelihood of LVH [Exp (B)=2.20, P=0.048, logistic regression] and increased systolic blood pressure [Exp (B)=1.02, P=0.05, logistic regression]. Comparing mean sST2 concentrations (adjusted for age, body mass index, gender) between different LV remodeling patterns, we found the greatest sST2 level in the group with concentric hypertrophy. There were no differences in sST2 concentration between groups with and without LV DD. Conclusions: Increased sST2 concentration in patients with MetS was associated with a greater likelihood of exhibiting LVH. Our results suggest that inflammation could be one of the principal triggering mechanisms for LV remodeling in MetS.
참고문헌 (27)
- The IDF consensus worldwide definition of the metabolic syndrome, "Alberti G", International Diabetes Federation, ~ (2006)
- Hunt KJ, "National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study", Circulation, 110, pp.1251~1257 (2004)
- 김성환, "Metabolic Syndrome and Myocardial Contractile Reserve", Journal of Cardiovascular Ultrasound, 19(4), pp.174~175 (2011), 한국심초음파학회
- de las Fuentes L, "Metabolic syndrome is associated with abnormal left ventricular diastolic function independent of left ventricular mass", Eur Heart J, 28, pp.553~559 (2007)
- Tadic M, "Metabolic syndrome and left ventricular function: is the number of criteria actually important?", Med Sci Monit, 18, pp.282~289 (2012)
- O’Neil L, "The Toll", interleukin-1 receptor domain: a molecular switch for inflammation and host defence, 2000, pp.28, 557~563
- Shimpo M, "Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction", Circulation, 109, pp.2186~2190 (2004)
- Rehman SU, "Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure", J Am CollCardiol, 52, pp.1458~1465 (2008)
- Weinberg EO, "Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction", Circulation, 106, pp.2961~2966 (2002)
- Weinberg EO, "Identification of serum soluble ST2 receptor as a novel heart failure biomarker", Circulation, 107, pp.721~726 (2003)
- Coglianese EE, "Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study", Clin Chem, 58, pp.1673~1681 (2012)
- Ojji DB, "Relationship between left ventricular geometry and soluble ST2 in a cohort of hypertensive patients", J Clin Hypertens, 15, pp.899~904 (2013)
- Zeyda M, "Severe obesity increases adipose tissue expression of interleukin-33 and its receptor ST2, both predominantly detectable in endothelial cells of human adipose tissue", Int J Obes, 37, pp.658~665 (2013)
- Fousteris E, "Toll", interleukin-1 receptor member ST2 exhibits higher soluble levels in type 2 diabetes, especially when accompanied with left ventricular diastolic dysfunction, 2011, pp.10, 101~
- Chen LQ, "Soluble ST2 is associated with all-cause and cardiovascular mortality in a population-based cohort: the Dallas Heart Study", Clin Chem, 59, pp.536~546 (2013)
- Mancia G, "2013 ESH", ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), 2013, pp.34, 2159~2219
- Alberti KG, "Harmonizing the metabolic syndrome:ajoint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention", Circulation, 120, pp.1640~1645 (2009)
- Alberti KG, "Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation", Diabet Med, 23, pp.469~480 (2006)
- Lang RM, "Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging", J Am Soc Echocardiogr, 28, pp.1~39 (2015)
- Quiñones MA, "Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography", J Am Soc Echocardiogr, 15, pp.167~184 (2002)
- Nagueh SF, "Recommendations for the evaluation of left ventricular diastolic function by echocardiography", Eur J Echocardiogr, 10, pp.165~193 (2009)
- Oh JK, "Established and novel clinical applications of diastolic function assessment by echocardiography", Circ Cardiovasc Imaging, 4, pp.444~455 (2011)
- Westcott DJ, "MGL1 promotes adipose tissue inflammation and insulin resistance by regulating 7", 4hi monocytes in obesity, 2009, pp.206, 3143~3156
- Ciccone MM, "A novel cardiac bio-marker: ST2: areview", Molecules, 18, pp.15314~15328 (2013)
- Garlanda C, "The interleukin-1 family: back to the future", Immunity, 39, pp.1003~1018 (2013)
- Demyanets S, "Components of the interleukin-33", ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature, 2013, pp.60, 16~26
- Wang YC, "Soluble ST2 as a biomarker for detecting stable heart failure with a normal ejection fraction in hypertensive patients", J Card Fail, 19, pp.163~168 (2013)